Treatment Chronic UTI Post Kidney Transplant

Phase 3TerminatedNCT05967130

Shahid Beheshti University of Medical Sciences5 enrolled

Overview

Urinary tract infections (UTIs) with extended-spectrum -lactamase (ESBL)-positive Enterobacteriums (ESBL-E) are a common infectious complication of renal transplant recipients, with 10% of patients suffering from UTIs with ESBL-E within the first year posttransplant. Moreover, recurrence rates of UTI caused by ESBL-E are almost three times higher than those by cephalosporin-susceptible Enterobacteriums demonstrating the decreased efficacy of antibiotics in the treatment of these UTIs.

According to each patient's urine culture, resistant urinary tract infections will be treated with specific phages and patients will be followed up with their urine cultures for response to therapy.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Urinary Tract Infections Transplant-Related Disorder

Interventions

PhageBIOLOGICAL

Inserting specific specimen of phages in to the bladder

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Stable Kidney Transplant Recipients * Stable Immunosupression Dose * Stable Renal Function * Resistant Urinary Infection with Positive UC Exclusion Criteria: * Rejection periods * Frail Patients

Locations (1)

Nooshin Dalili

Tehran, Iran

Outcomes

Primary Outcomes

Urine culture

Negative Urine Culture

Time frame: 1 week after administration

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.